Buccal Delivery Systems Market Investigated by MP Advisors in Cutting-Edge Study Available at MarketPublishers.com
14 Oct 2015 • by Natalie Aster
LONDON – Buccal drug delivery is a promising area for future research for purposes of systemic delivery of orally less efficient drugs and also a feasible and attractive option for noninvasive delivery of potent peptide and protein drug molecules. As of 2014, sales of Suboxone sublingual film amounted to close to USD 1.3 billion in the USA whilst the total market value reached over USD 1.7 billion, fueled by an 11% rise in prescriptions. In 2014, Bunavail buccal film got approved by FDA, which has similar suboxone bioavailability with half of the dose of buprenorphine.
Other than drugs utilised for local actions, generally controlled substances such as buprenorphine, naloxone and fentanyl are favoured to release the drug through buccal formulations. Nevertheless, testosterone (striant) to treat low levels of testosterone in men also approved through usage of buccal delivery system. Across the USA, such drugs as Isosorbide dinitrate (ISDN), ergoloid delivered sublingually have been discontinued and nitroglycerin has been substituted with sublingual metered spray. Ergomar, a drug marketed by Rosedale therapeutics, is the only sublingual tablets present in the US market, priced USD 15 per pill. Insys therapeutics’ Subsys was the sublingual spray recenty approved by FDA to treat breakthrough cancer pain.
New report “Buccal Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays – Detailed Analysis on Technologies and Pipeline Development” created by MP Advisors provides a granular analysis on buccal delivery systems in the broader pharmaceuticals market in finding companies and technologies and complexities engaged in developing the exclusive high potential delivery system. The study provides detailed information on the types of dosage forms, reviews transmucosal delivery systems, sheds light on the potential benefits of buccal films, discusses the challenges and limitations of buccal delivery systems. It gives an overview of buccal films, buccal tablets, sublingual films and/or tablets, and other technologies used in buccal delivery systems. The report analyses oral thin fast dissolving films (OTF), covering their ideal characteristics, classification, etc. Furthermore, an in-depth analysis of the leading companies is provided as well.
Buccal Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays – Detailed Analysis on Technologies and Pipeline Development
Published: October, 2015
Price: US$ 3,000.00
More studies by the publisher can be found at MP Advisors page.